Loading
GRHPR (Glyoxylate reductase/hydroxypyruvate reductase) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Enzyme with hydroxy-pyruvate reductase, glyoxylate reductase and D-glycerate dehydrogenase enzymatic activities. Reduces hydroxypyruvate to D-glycerate, glyoxylate to glycolate, oxidises D-glycerate to hydroxypyruvate.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · GRHPR (Glyoxylate reductase/hydroxypyruvate reductase) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
GRHPR (Glyoxylate reductase/hydroxypyruvate reductase) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Enzyme with hydroxy-pyruvate reductase, glyoxylate reductase and D-glycerate dehydrogenase enzymatic activities. Reduces hydroxypyruvate to D-glycerate, glyoxylate to glycolate, oxidises D-glycerate to hydroxypyruvate.
No product in this corpus aims at GRHPR yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA GRHPR: RNA tissue enhanced (liver 610 nTPM); high antibody staining in 5 normal tissues; highest cancer staining thyroid cancer (3 of 4 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas GRHPR tissue; Open Targets ENSG00000137106 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Liu et al, 1998. Source.
Sources: HGNC HGNC:4570 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UBQ7 (protein name, function text, keywords and locations (REST API)); CIViC gene GRHPR (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0))
Enzyme with hydroxy-pyruvate reductase, glyoxylate reductase and D-glycerate dehydrogenase enzymatic activities. Reduces hydroxypyruvate to D-glycerate, glyoxylate to glycolate, oxidises D-glycerate to hydroxypyruvate. Locus 9p13.2 (HGNC).
RNA: tissue enhanced (liver 610 nTPM), detected in all normal tissues.
Medium: Appendix, Breast, Caudate, Duodenum, Endometrium, Gallbladder, Liver, Salivary gland.
Medium only: colorectal cancer, head and neck cancer, lung cancer, melanoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GRHPR" OR ABSTRACT:"GRHPR" OR TITLE:"glyoxylate and hydroxypyruvate reductase" OR ABSTRACT:"glyoxylate and hydroxypyruvate reductase" OR TITLE:"Glyoxylate reductase/hydroxypyruvate reductase" OR ABSTRACT:"Glyoxylate reductase/hydroxypyruvate reductase" OR TITLE:"PH2" OR ABSTRACT:"PH2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GRHPR, not a curated reading list.